Search results for "Highlights"
Review finds upadacitinib most effective for moderate to severe ulcerative colitis remission
The systematic review and meta-analysis of biologic and small-molecule drugs for patients with moderate to severe ulcerative colitis also found that upadacitinib ranked highest for adverse events, whereas vedolizumab had the lowest rate of adverse events and serious adverse events.
https://gastroenterology.acponline.org/archives/2021/12/17/2.htm
17 Dec 2021
AGA releases new guidance on coagulation disorders in patients with cirrhosis
A clinical practice guideline from the American Gastroenterological Association (AGA) suggested against extensive preprocedural testing in patients with stable cirrhosis who are undergoing routine GI procedures, among other recommendations.
https://gastroenterology.acponline.org/archives/2021/11/19/3.htm
19 Nov 2021
Colonoscopy common, riskier in those with life expectancy of less than 10 years
A study of patients undergoing screening colonoscopy after age 75 years found that relatively few cancers were found and treated and that the risk of adverse events requiring hospitalization was high and rose with age.
https://gastroenterology.acponline.org/archives/2023/04/21/1.htm
21 Apr 2023
Self-administered questionnaire may help evaluate patients' cirrhosis knowledge
The questionnaire, which covered medication use and accessibility, medication obstacles, lactulose use, diuretic use, beta-blocker use, and dietary sodium use, was validated in a study of 582 outpatients and 131 inpatients.
https://gastroenterology.acponline.org/archives/2022/09/23/1.htm
23 Sep 2022
New best practice advice tackles pain in disorders of gut-brain interaction
An expert review from the American Gastroenterological Association cautioned against using opioids to treat pain from irritable bowel syndrome, functional dyspepsia, or centrally mediated abdominal pain syndrome, among other advice.
https://gastroenterology.acponline.org/archives/2021/07/23/2.htm
23 Jul 2021
Novel therapy may be effective treatment for H. pylori infection, industry-funded trial finds
About 84% of participants randomly assigned to receive rifabutin in addition to amoxicillin and omeprazole achieved Helicobacter pylori eradication, compared to 58% of those who received amoxicillin and omeprazole alone.
https://gastroenterology.acponline.org/archives/2020/05/22/2.htm
22 May 2020
Person-to-person transmission now more common source of hepatitis A in U.S. than food
An analysis of hepatitis outbreaks in 2016 to 2020, comprising 37,553 cases, found that 56% of patients reported drug use, 14% reported homelessness, 12% reported recent incarceration, and 3% reported recent international travel.
https://gastroenterology.acponline.org/archives/2022/10/28/1.htm
28 Oct 2022
H. pylori eradication therapy may lead to better outcomes for functional dyspepsia
A systematic review and meta-analysis found that Helicobacter pylori eradication therapy was associated with higher cure rates and rates of symptom improvement in H. pylori-positive patients with functional dyspepsia.
https://gastroenterology.acponline.org/archives/2022/01/28/2.htm
28 Jan 2022
Elimination diets effective for patients with eosinophilic esophagitis
A systematic review and meta-analysis of 34 studies found that a six-food elimination diet was not significantly better than less restrictive dietary regimens for histological remission and clinical symptom improvement.
https://gastroenterology.acponline.org/archives/2023/02/24/1.htm
24 Feb 2023
Guideline recommends multiple drug classes to treat adults with moderate to severe luminal, fistulizing Crohn's disease
A new clinical practice guideline from the American Gastroenterological Association offered recommendations on which drug classes to use for induction and maintenance of remission, as well as some combination therapies.
https://gastroenterology.acponline.org/archives/2021/06/25/2.htm
25 Jun 2021